Table 4

Clinical diagnosis and treatment parameters

Parameter

Parameter estimate


Hysterectomy for non-HPV-related conditions, % per year [93]

15–24 years

0.02

25–29 years

0.26

30–34 years

0.53

35–39 years

0.89

40–44 years

1.17

45–54 years

0.99

≥ 55 years

0.36

Cervical cytology screening, % per year (excluding those with hysterectomy) [47]

10–14 years

0.6 (0.6)

15–19 years

21.0 (21.0)

20–24 years

44.6 (44.8)

25–29 years

60.4 (61.6)

30–34 years

52.4 (54.9)

35–39 years

46.0 (50.5)

40–44 years

41.0 (48.1)

45–49 years

39.1 (49.1)

50–54 years

38.0 (51.1)

55–59 years

33.2 (46.7)

60–64 years

29.4 (42.5)

65–69 years

26.2 (38.9)

70–74 years

19.4 (29.6)

75–79 years

12.9 (20.1)

80–84 years

7.0 (11.1)

85+

3.4 (5.5)

Women never screened, %

5.0

Liquid-based cytology sensitivity, %

for CIN 1 [114]

28

for ≥ CIN 2/3 [115]

59

Liquid-based cytology specificity, % [114,115]

94

Colposcopy sensitivity, % [117]

96

Colposcopy specificity, % [117]

48

Symptom development, % per year

for LCC

4

for RCC

18

for DCC

90

Eradication with treatment, %

for CIN1 [118-124]

97

for CIN2 [118,122,124,125]

93

for CIN3 [118,122,124,125]

93

for LCC [89]

92

for RCC [89]

55

for DCC [89]

17

for anogenital warts [41]

87.5/year

Persistence of HPV following eradication of CIN, % [127]

34

Persistence of HPV following eradication of cervical cancer, % [129]

47

Persistence of HPV following eradication of genital warts

34

Anogenital wart patients seeking physician care, % [71]

75


CIN = cervical intraepithelial neoplasia; DCC = distant cervical cancer; HPV = human papillomavirus; LCC = localized cervical cancer; RCC = regional cervical cancer

Insinga et al. BMC Infectious Diseases 2009 9:119   doi:10.1186/1471-2334-9-119

Open Data